Annual report pursuant to Section 13 and 15(d)

Cover

v3.25.0.1
Cover - USD ($)
$ / shares in Units, $ in Millions
 12 Months Ended
Dec. 31, 2024
Feb. 19, 2025
Jun. 30, 2024
Cover [Abstract]      
Document Type 10-K    
Amendment Flag false    
Document Annual Report true    
Document Transition Report false    
Document Period End Date Dec. 31, 2024    
Document Fiscal Period Focus FY    
Document Fiscal Year Focus 2024    
Current Fiscal Year End Date --12-31    
Entity File Number 001-40023    
Entity Registrant Name GT BIOPHARMA, INC.    
Entity Central Index Key 0000109657    
Entity Tax Identification Number 94-1620407    
Entity Incorporation, State or Country Code DE    
Entity Address, Address Line One 315 Montgomery Street    
Entity Address, Address Line Two 10th Floor    
Entity Address, City or Town San Francisco    
Entity Address, State or Province CA    
Entity Address, Postal Zip Code 94104    
City Area Code (415)    
Local Phone Number 919-4040    
Title of 12(b) Security Common Stock, $0.001 Par Value    
Trading Symbol GTBP    
Security Exchange Name NASDAQ    
Entity Well-known Seasoned Issuer No    
Entity Voluntary Filers No    
Entity Current Reporting Status Yes    
Entity Interactive Data Current Yes    
Entity Filer Category Non-accelerated Filer    
Entity Small Business true    
Entity Emerging Growth Company false    
Entity Shell Company false    
Entity Public Float     $ 5.1
Entity Common Stock, Shares Outstanding   2,234,328  
ICFR Auditor Attestation Flag false    
Document Financial Statement Error Correction [Flag] false    
Entity Listing, Par Value Per Share $ 0.001    
Auditor Name Weinberg & Company, P.A    
Auditor Firm ID 572    
Auditor Location Los Angeles, California